Hepatocellular carcinoma pathogenesis: Does PPAR alpha polymorphism have a role in hepatocarcinogenesis associated with HBV and HCV infections?

Turkish Journal of Gastroenterology

Volumn 19, Issue 4, 2008, Pages 231-233

  Akkiz, Hikmet ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLATELET DERIVED GROWTH FACTOR B; TELOMERASE REVERSE TRANSCRIPTASE;

CANCER GROWTH; CANCER RISK; CONFERENCE PAPER; DISEASE ASSOCIATION; DNA METHYLATION; DNA POLYMORPHISM; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PATHOGENESIS;

CARCINOMA, HEPATOCELLULAR; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; POLYMORPHISM, GENETIC;

EID: 58149092651     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Block TM, Mehta AS, Fimmel CJ, et al. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003;22:5093-107.
2. Lotz G, Kiss A, Novak PK, et al. Hepatitis viruses and hepatocarcinogenesis. J Physiol Paris 2001;95:417-22.
3. Buendia MA. Genetics of hepatocellular carcinoma. Semin Cancer Biol 2000;10:185-200.
4. Berchot C, Gözüaçik D, Murakami Y, et al. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol 2000;10:211-31.
5. Koike K. Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways. J Gastroenterol Hepatol 2007;22:108-11.
6. Gronbaek K, Hother C, Jones PA. Epigenetic changes in cancer. APMIS 2007;115:1039-59.
7. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction. Nat Rev Cancer 2006;6:107-15.
8. Wiemann SU, Satyanarayana A, Tsahuridu M, et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J 2002;16:935-42.
9. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al. A DNA damage check point response in telomere-initiated senescence. Nature 2003;426:194-8.
10. Artanti SE, Chang S, Lee SL, et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000;406:641-5.
11. Pelentz RR, Caselitz M, Bleck JS, et al. Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatoma. Hepatology 2004;40:80-6.
12. Plentz RR, Park YN, Lechel A, et al. Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology 2007;45:968-76.
13. Huang H, Fuji H, Sankila A, et al. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol 1999;155:1795-801.
14. El-Serag H, Rudolph LK. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76.
15. Wright WE, Shay JW. The two stage mechanism controlling cellular senescence and immortalization. Ex Gerontol 1992;27:383-9.
16. Farazi PA, DePinto RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nature 2006;6:674-86.
17. Michalic L, Desvergne B, Wahli W. Peroxisome-proliferators-activated receptors and cancers: complex stories. Nature 2004;4:61-70.
18. Borbath I, Horsmans Y. The role of PPAR gamma in hepatocellular carcinoma PPAR Res 2008;2008:209520.
19. Genini D, Carbone GM, Catapone CV. Multiple interactions between Peroxisome Proliferators-Activated Receptors and the Ubiquitin-Proteasome System and implications for cancer pathogenesis. PPAR Res 2008;2008:195065.
20. Peters JM, Cattley RC, Gonzalez FJ. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14.643. Carcinogenesis 1997;18:2029-33.